content

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

GW Pharmaceuticals plc , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. ...

Intarcia Announces FDA Filing Acceptance of NDA for ITCA 650 for the Treatment of Type 2 Diabetes

Intarcia Therapeutics, Inc. announced that the U.S. FDA has accepted for active review its NDA for ITCA 650, an investigational therapy for the treatment...

Envisia therapeutics releases interim Env515 phase 2 data results 

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology released an interim analysis of the second cohort...

Arven Pharmaceuticals selects GE Healthcare’s FlexFactory to improve Turkish and regional access to biopharmaceuticals

Arven Pharmaceuticals, a Toksoz Group Company, has selected GE Healthcare’s FlexFactory manufacturing platform to expand production capacity at its facility in Kirklareli, Turkey. ...

MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS

MeiraGTx, a New York and UK based gene therapy company, announced that it has been awarded a grant from Target ALS, a privately funded...

Sanofi and Regeneron Announce First  Approval of KevzaraTM for the Treatment of Moderately

Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody. For the treatment of...

MDCPartners launches new ta-Scan software that ‘will revolutionize’ the way pharmaceutical companies plan for the future

MDCPartners  launches ta-Scan 5, an update of its global web-based platform that analyses clinical trial data. The new platform is set to revolutionize the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read